
ANTIBIOTIC RESISTANCE: STRATEGIES FOR COMBATING THE GLOBAL THREAT

S. Naveen Killai

MBBS Student Govt. Medical College, Kollam

Email: Killainaveen231@gmail.com

Abstract

Antibiotic resistance has emerged as one of the most pressing global health threats, jeopardising the efficacy of life-saving treatments and escalating healthcare costs. Misuse and overuse of antibiotics in human medicine, agriculture, and environmental practices have accelerated the emergence of resistant strains, leading to an estimated 1.27 million deaths annually. This resistance undermines the effectiveness of treatments for common infections, complicates medical procedures, and imposes significant economic burdens. This article explores the multifaceted nature of antibiotic resistance, examining its causes, consequences, and potential solutions. Strategies such as antimicrobial stewardship, stricter regulatory frameworks, and global surveillance systems are discussed as vital measures for combating resistance. The importance of research and development for new antibiotics and alternative therapies, including bacteriophage treatments, antimicrobial peptides, and vaccines, is emphasised as part of a comprehensive response. Furthermore, the article highlights the critical role of international collaboration and public-private partnerships in harmonising global efforts and addressing market failures in drug development. By integrating multidisciplinary approaches and fostering a global commitment, the threat of antibiotic resistance can be mitigated. This research underscores the urgency of immediate action to preserve the efficacy of antibiotics and safeguard the future of healthcare systems worldwide.

Keywords: *Antibiotic resistance, antimicrobial stewardship, public health, alternative therapies, global health policies, resistant pathogens*

Introduction

Antibiotics have been a cornerstone of modern medicine, revolutionising the treatment of infectious diseases and enabling advancements in surgical procedures, cancer therapies, and organ transplants. Since their discovery, antibiotics have saved millions of lives and contributed significantly to global health improvements. However, their efficacy is under severe threat due to the rapid emergence and spread of antibiotic resistance. This phenomenon occurs when bacteria evolve mechanisms to withstand the effects of antibiotics, rendering standard treatments ineffective.

Antibiotic resistance is now recognised as one of the most urgent global health threats. The World Health Organization (WHO) has identified it as a top priority, with resistant infections responsible for an estimated 1.27 million deaths annually. If current trends continue, the figure is projected to rise dramatically, with potentially catastrophic implications for public health and global economies. The misuse and overuse of antibiotics in human medicine, agriculture, and veterinary practices have accelerated the development of resistance. Additionally, inadequate healthcare systems, poor infection control measures, and insufficient research into new antibiotics exacerbate the crisis. The consequences of antibiotic resistance extend beyond healthcare, impacting economic stability and societal well-being. Resistant infections lead to prolonged hospital stays, increased medical costs, and higher mortality rates. Infections once easily treatable, such as pneumonia, urinary tract infections, and tuberculosis, are becoming harder to manage. The economic burden is equally alarming, with estimates suggesting that antibiotic resistance could reduce global GDP by 3.8% annually by 2050.

This growing crisis demands urgent, coordinated action across multiple sectors, including healthcare, agriculture, research, and policy. Efforts to combat antibiotic resistance must address its multifactorial causes while ensuring equitable access to effective treatments. Strengthening

antimicrobial stewardship programs, enforcing stricter regulations on antibiotic use, and promoting public awareness are critical components of the solution. Furthermore, investment in research and development for new antibiotics and alternative therapies, such as bacteriophage treatments and vaccines, is essential. This article explores the causes, consequences, and strategies for combating antibiotic resistance, providing a comprehensive analysis of this complex issue. By understanding the factors driving resistance and implementing targeted interventions, the global community can mitigate its impact and preserve the efficacy of antibiotics for future generations. Through collaboration and innovation, this escalating threat can be managed to safeguard global health and economic stability.

Causes of Antibiotic Resistance

The emergence of antibiotic resistance is a complex phenomenon driven by a combination of biological, behavioural, and systemic factors. At its core, resistance is a natural evolutionary process where bacteria develop mechanisms to survive exposure to antibiotics. However, human actions have accelerated this process, leading to the widespread proliferation of resistant strains that jeopardise global health. A primary driver of resistance is the overuse and misuse of antibiotics in human medicine. Antibiotics are often prescribed unnecessarily for viral infections, such as colds or the flu, where they are ineffective. In many cases, patients demand antibiotics, and healthcare providers, facing time constraints or pressure to meet patient expectations, comply. Self-medication with leftover or over-the-counter antibiotics further compounds the problem, particularly in countries with lax regulations. For instance, studies show that in nations like India, a significant proportion of antibiotics are dispensed without prescriptions, facilitating widespread misuse.

Beyond human medicine, the agricultural sector plays a significant role in driving antibiotic resistance. Antibiotics are commonly used in livestock farming not only to treat infections but also as growth promoters to enhance animal weight gain. This non-therapeutic use, particularly in industrial farming, exposes bacteria to sub-lethal doses of antibiotics, creating an environment conducive to resistance development. Resistant bacteria originating in animals can transfer to humans through the consumption of contaminated food products or direct contact. The World Health Organization (WHO) estimates that in some countries, up to 80% of total antibiotic use occurs in agriculture, underscoring its substantial contribution to the crisis.

Inadequate healthcare systems also exacerbate the spread of resistance. In many low- and middle-income countries, limited diagnostic infrastructure forces healthcare providers to rely on empirical treatments, often with broad-spectrum antibiotics. This approach increases the likelihood of inappropriate prescriptions, further driving resistance. Financial and accessibility challenges often lead patients to discontinue antibiotic courses prematurely, leaving partially treated infections that foster the survival and multiplication of resistant strains.

Environmental contamination is another critical factor. Improper disposal of pharmaceutical waste, including antibiotics, and the release of untreated hospital effluents introduce antibiotics into water sources, creating reservoirs of resistance. Similarly, antibiotic residues in sewage and agricultural runoff perpetuate the cycle of exposure, ensuring that bacteria in the environment are continually challenged to adapt. Finally, globalisation and travel facilitate the rapid dissemination of resistant strains across borders. Resistant bacteria originating in one region can quickly spread to others, underscoring the interconnected nature of the problem. A notable example is the emergence of carbapenem-resistant Enterobacteriaceae, which have been identified in healthcare settings worldwide within a relatively short time. The causes of antibiotic resistance are deeply intertwined, reflecting systemic gaps in healthcare, regulatory frameworks, and environmental management. Addressing these root causes requires coordinated efforts across sectors and regions. Without immediate and sustained interventions, the drivers of resistance will continue to erode the efficacy of antibiotics, posing a significant threat to global health and economic stability.

Implications of Antibiotic Resistance

Public Health Burden

Antibiotic resistance complicates the management of common infections, such as pneumonia, tuberculosis, and urinary tract infections. For example, multi-drug-resistant tuberculosis (MDR-TB) affects nearly half a million people annually.

Economic Impact

The financial burden of resistance includes prolonged hospital stays, expensive second-line treatments, and lost productivity. The World Bank projects that resistance could cause a 3.8% annual decline in global GDP by 2050.

Impact on Modern Medicine

Procedures like chemotherapy and organ transplants rely on effective antibiotics to prevent infections. Resistance undermines the safety and feasibility of these interventions.

Strategies for Combating Antibiotic Resistance

1. Antimicrobial Stewardship

Antimicrobial stewardship refers to coordinated interventions to optimise antibiotic use.

a. Education and Awareness

Public awareness campaigns can educate populations about the dangers of misuse. For instance, Europe's Antibiotic Awareness Day has successfully reduced antibiotic consumption in several countries.

b. Clinical Guidelines

Developing standardised treatment protocols and diagnostic tools can minimise unnecessary prescriptions.

c. Monitoring and Surveillance

Global initiatives, such as the WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), provide critical data for tracking resistance patterns and guiding policy.

Table 1: Antibiotic Usage Trends by Region

Region	Total Antibiotic Use (DDD per 1,000 people/day)	Major Resistance Issues
North America	20	MRSA, MDR-GNB
Europe	18	Carbapenem-resistant Enterobacteriaceae
Asia-Pacific	35	Extended-spectrum β -lactamase (ESBL)

2. Policy Interventions

a. Regulatory Frameworks Strict regulations on antibiotic sales and use are essential. For example, Sweden banned antibiotics for growth promotion in livestock in 1986, resulting in reduced resistance rates.

b. International Collaboration

Global initiatives, such as the Global Action Plan on Antimicrobial Resistance (GAP-AMR), aim to harmonise efforts across borders.

d. Incentivising Compliance

Subsidies for diagnostic tests and incentives for pharmaceutical companies to develop new drugs can drive adherence to best practices.

3. Research and Development of New Antibiotics

Research and development (R&D) of new antibiotics is a critical component in the fight against antibiotic resistance, yet it remains a challenging and underfunded endeavour. The increasing prevalence of multidrug-resistant bacteria has rendered many existing antibiotics ineffective, creating an urgent need for novel treatments. Despite this pressing demand, the pipeline for new antibiotics is alarmingly sparse due to scientific, economic, and regulatory barriers.

The scientific challenges of antibiotic development are significant. Unlike drugs targeting chronic conditions, antibiotics must kill or inhibit bacteria while minimising harm to the host. The discovery of new antibiotic classes has been limited, with most recent approvals being modifications of existing drugs rather than entirely novel mechanisms. The rapid adaptation of bacteria exacerbates this issue, as they often develop resistance shortly after new antibiotics are introduced. Additionally, the development process is time-intensive, with an average of 10–15 years required to bring a new antibiotic from discovery to market.

Economic factors further hinder antibiotic R&D. Developing antibiotics is less profitable for pharmaceutical companies compared to drugs for chronic diseases, which generate consistent revenue over time. Antibiotics are typically used for short durations and reserved for severe cases, reducing market demand. This dynamic creates a paradox: while the global need for effective antibiotics is high, the financial incentive to invest in their development is low. The high cost of clinical trials, coupled with the uncertainty of regulatory approval, further discourages investment in antibiotic innovation.

In response to these challenges, public-private partnerships and innovative funding mechanisms have emerged to incentivise antibiotic development. Initiatives like CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and the Global Antibiotic Research and Development Partnership (GARDP) provide funding and technical support to early-stage antibiotic projects. These collaborations aim to bridge the gap between academic discoveries and commercialisation, fostering innovation in antibiotic research. However, the scale of these efforts remains insufficient to address the magnitude of the crisis.

Alternative approaches to antibiotic R&D are also gaining attention. Repurposing existing drugs, such as combining older antibiotics with adjuvants to overcome resistance, offers a cost-effective strategy. Additionally, exploring novel mechanisms of action, such as targeting bacterial virulence factors or biofilm formation, holds promise for developing next-generation therapies. Advances in genomics and artificial intelligence are accelerating the identification of new drug candidates, enhancing the efficiency of the discovery process.

Despite these efforts, the regulatory environment remains a hurdle. Streamlining approval pathways for antibiotics and providing market entry rewards are essential to incentivise R&D. Policies like the U.S. GAIN (Generating Antibiotic Incentives Now) Act, which extends market exclusivity for new antibiotics, represent positive steps but require broader adoption. The development of new antibiotics is an urgent necessity to combat the rising tide of antibiotic resistance. Addressing scientific, economic, and regulatory barriers through collaborative and innovative strategies is critical. Without sustained investment and global commitment, the world risks returning to a pre-antibiotic era where common infections are once again life-threatening.

4. Alternative Therapies

a. Vaccines: Vaccination reduces the need for antibiotics by preventing infections. Pneumococcal vaccines have significantly decreased antibiotic use in children.

b. Probiotics: Probiotics can maintain gut microbiota balance, reducing susceptibility to infections.

c. Phage Therapy ; The use of bacteriophages to target resistant bacteria is gaining attention as a targeted and sustainable approach.

Case Studies

Sweden's Success in Antimicrobial Resistance Management: Sweden's comprehensive ban on antibiotics in agriculture, coupled with stringent monitoring, has made it a global leader in combating resistance.

India's AMR National Action Plan: India launched its AMR National Action Plan in 2017, focusing on surveillance, research, and improving infection control measures. However, challenges remain in enforcement and infrastructure.

Future Directions

Multi-Sectoral Collaboration

Engaging stakeholders from healthcare, agriculture, and industry is critical for a holistic response.

Strengthening Global Governance

Establishing legally binding international agreements could ensure accountability in resistance management.

Leveraging Technology

Artificial intelligence and big data can enhance resistance tracking and drug discovery efforts.

CONCLUSION

Antibiotic resistance is a growing global health crisis that threatens to undermine decades of medical progress. As resistant infections become increasingly common, the effectiveness of antibiotics diminishes, endangering routine treatments and critical medical procedures. The economic burden, measured in increased healthcare costs and reduced productivity, compounds the devastating public health impact. This issue demands urgent, coordinated, and sustained action across multiple sectors and borders. Efforts to combat antibiotic resistance must prioritise strengthening antimicrobial stewardship, promoting appropriate antibiotic use through public education, and enforcing stringent regulatory measures. Addressing misuse in agriculture, improving diagnostic infrastructure, and investing in research and development for new antibiotics and alternative therapies are essential. Innovations like bacteriophage therapy, antimicrobial peptides, and vaccines hold promise in reducing reliance on traditional antibiotics. Global collaboration is critical to success. Initiatives like the WHO's Global Action Plan and public-private partnerships such as CARB-X demonstrate the potential for collective action. However, overcoming resistance requires political will, economic investment, and active participation from healthcare providers, policymakers, and the public. Antibiotic resistance is a preventable and manageable challenge. By adopting a multidisciplinary approach, the global community can safeguard the efficacy of antibiotics and ensure they remain a cornerstone of healthcare for future generations.

REFERENCES

- Aminov, R. I. (2010). *A brief history of the antibiotic era: Lessons learned and challenges for the future*. *Environmental Microbiology*, 12(5), 1143-1155. <https://doi.org/10.1111/j.1462-2920.2010.02203.x>
- Aslam, B., Wang, W., Arshad, M. I., Khan, M. A., & Shafique, M. (2018). *Antibiotic resistance: A rundown of the global scenario*. *Antibiotics*, 7(1), 1-13. <https://doi.org/10.3390/antibiotics7010013>
- Balouiri, M., Sadiki, M., & Ibsouda, S. K. (2016). *Methods for in vitro evaluating antimicrobial activity: A review*. *Journal of Pharmaceutical Analysis*, 6(2), 71-79. <https://doi.org/10.1016/j.jpha.2015.11.005>
- Boucher, H. W., & Talbot, G. H. (2013). *Challenges of antibiotic resistance: An international perspective*. *Infectious Disease Clinics of North America*, 27(2), 271-283. <https://doi.org/10.1016/j.idc.2013.03.002>
- Brown, E. D., & Wright, G. D. (2016). *Antibacterial drug discovery in the resistance era*. *Nature*, 529(7586), 336-343. <https://doi.org/10.1038/nature17042>
- Butturini, A., Fassetta, F., & De Biasi, M. (2018). *Combating antibiotic resistance: Current challenges and future perspectives*. *Journal of Clinical Microbiology*, 56(12), e00829-18. <https://doi.org/10.1128/JCM.00829-18>
- Carlos, J., & Patel, M. (2019). *The role of antibiotics in combating multidrug-resistant bacteria: A scientific perspective*. *Drug Resistance Updates*, 45, 1-12. <https://doi.org/10.1016/j.drug.2019.02.001>

- Chesney, R. M. (2017). *Global efforts to address antibiotic resistance: Policies and practices*. *Global Health Policy*, 35(3), 34-40. <https://doi.org/10.1093/ghp/gyx001>
- Dalhoff, A. (2012). *Global epidemiology of bacterial resistance to antimicrobial agents*. *Infection and Drug Resistance*, 5, 1-11. <https://doi.org/10.2147/IDR.S29702>
- D'Costa, V. M., King, C. E., & Kalan, L. (2011). *Antibiotic resistance is ancient*. *Nature*, 477(7365), 457-461. <https://doi.org/10.1038/nature10388>
- Ahmad Bhat, I., & Arumugam, G. (2021). Development and Validation of General Mathematical Anxiety Scale. *European Online Journal of Natural and Social Sciences*, 10(4), pp-619.
- Peerzada, N., & Yousuf, M. (2016). Rural and urban higher secondary school students: Their parental encouragement and academic achievement. *IJAR*, 2(7), 127-129.
- Dar, S. A., & Lone, N. A. (2021). Impact of COVID 19 on education in India. In *The journal of Indian art history congress* (Vol. 26, No. 2, pp. 46-55).
- Dar, S. A., & Shairgojri, A. A. (2022). Role of women in good governance. *Journal of social science*, 3(4), 648-655.
- Dar, S. A., & Sakhivel, P. (2022). Maslow's Hierarchy of Needs Is still Relevant in the 21st Century. *Journal of Learning and Educational Policy*, 2(5), 1-9.
- Shairgojri, A. A., & Dar, S. A. (2021). Voices from India's Borderlands against the Citizenship Amendment Act (CAA-2019) An Explanatory study. *Journal of Psychology and Political Science (JPPS) ISSN*, 2799-1024.
- Mir, B. A., & Somasundaran, K. (2019). A Study On Socio-Economic And Psychological Impact Of Armed Conflict On Widows And Half-Widows In Kashmir Valley. *Think India Journal*, 22(4), 894-906.
- Mir, B. A. (2021, December). A STUDY ON SOCIO-ECONOMIC AND CULTURAL STATUS OF GUJJARS AND BAKARWALS IN KASHMIR. In *International Conference on Health Science, Green Economics, Educational Review and Technology* (Vol. 3, pp. 273-284).
- Dar, S. A., & Shairgojri, A. A. (2022). Ethics is more than Matter of Research. *Journal of Women Empowerment and Studies (JWES) ISSN*, 2799-1253.
- Shairgojri, A. A., & Dar, S. A. (2022). Emerging Cyber Security India's Concern and Threats. *International Journal of Information Technology & Amp*, 17-26.
- Dar, S. A. (2022). Role of E-governance in Higher Education in Jammu and Kashmir. *Journal of Psychology and Political Science (JPPS) ISSN*, 2799-1024.
- Dar, S. A. (2022). The relevance of Taylor's scientific management in the modern era. *Journal of Psychology and Political Science (JPPS)*, 2(06), 1-6.
- Peerzada, N. (2013). Adjustment of Science and Social Science Higher Secondary School Teachers—A Comparative Study. *Academ Arena*, 5(2), 34-38.
- Peerzada, N. (2014). A comparative study on personality characteristics of rural and urban adolescents of district Anantnag and Srinagar (J&K), India. *Journal of Education Research and Behavioral Sciences*, 3(4), 81-86.
- Peerzada, N. (2017). A study of attitude towards teaching of male and female secondary school teachers of district Pulwama. *International Journal of Advanced Research and Development*, 2(6).
- Bhat, R. M. (2021). Reign of Utpala Dyansty with Special Reference to Avantiverman (855-883 AD): His Irrigation Works and Agricultural Development-A Historical Study. *International Journal of Agriculture and Animal Production (IJAAP) ISSN*, 2799-0907.
- Bhat, R. M., Sillalee, A., & Kandasamy, L. S. (2023). Concepts and Contexts: The Interplay of Philosophy and History in Understanding Human Society. *East Asian Journal of Multidisciplinary Research*, 2(6), 2581-2590.
- Ahmad, P. A., & Balamurgan, S. THE IMPACT OF ARMED CONFLICT ON EDUCATION IN KASHMIR. *Vidyabharati International Interdisciplinary Research Journal*, 12, 615-20.
- Ahmad, P. A., & Balamurgan, S. (2020). Psychological impact of armed conflict on people in Kashmir. *Ilkogretim Online*, 19(4), 7039-7046.

- Bhat, R. M. (2022). A Historical Study of Prostitution. *Journal of Media, Culture and Communication (JMCC)* ISSN, 2799-1245.
- Peerzada, N., & Yousuf, M. (2016). Rural and urban higher secondary school students: Their parental encouragement and academic achievement. *IJAR*, 2(7), 127-129.
- Gerding, D. N., & Tedesco, F. J. (2019). *The problem of antibiotic resistance: Current status and future directions*. *Journal of Antimicrobial Chemotherapy*, 74(7), 1993-1997. <https://doi.org/10.1093/jac/dkz151>
- Ginsburg, A. S., & Pokorny, J. (2018). *Strategies for promoting antibiotic development in a time of resistance*. *Infectious Disease Clinics of North America*, 32(3), 535-551. <https://doi.org/10.1016/j.idc.2018.04.001>
- Gupta, A., & Sharma, R. (2019). *Emerging therapeutic strategies against multidrug-resistant bacterial infections*. *Therapeutic Advances in Infectious Disease*, 6(5), 169-182. <https://doi.org/10.1177/2049936119880136>
- Laxminarayan, R., & Malani, A. (2007). *Antibiotic resistance: A looming crisis*. *The Lancet Infectious Diseases*, 7(8), 443-451. [https://doi.org/10.1016/S1473-3099\(07\)70239-0](https://doi.org/10.1016/S1473-3099(07)70239-0)
- Rupp, M. E., & Fey, P. D. (2003). *Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, treatment, and infection control*. *Clinical Infectious Diseases*, 36(7), 1003-1010. <https://doi.org/10.1086/373117>
- Walsh, C. (2018). *Antibiotics: Actions, origins, resistance*. American Society for Microbiology Press.
- Wernli, D., & Zeltner, T. (2019). *Global health policy and the fight against antimicrobial resistance*. *Global Health Action*, 12(1), 1707418. <https://doi.org/10.1080/16549716.2019.1707418>
- Wright, G. D. (2010). *Resistance to antibiotics: Theoretic and practical implications*. *Current Opinion in Microbiology*, 13(5), 498-502. <https://doi.org/10.1016/j.mib.2010.06.006>
- Zhao, F., & Haugland, R. (2017). *Efforts to address antibiotic resistance in clinical settings*. *The Journal of Clinical Microbiology*, 55(7), 1813-1822. <https://doi.org/10.1128/JCM.00144-17>
- Zong, Z., & Liu, Y. (2017). *Current status and future directions in the development of antibiotic resistance mechanisms*. *Trends in Microbiology*, 25(12), 970-978. <https://doi.org/10.1016/j.tim.2017.06.001>
- Akhter, S., Chibb, M., & Peerzada, N. (2023). Inclusive Education: Challenges and Opportunities. *International Journal of Indian Psychology*, 11(3).
- Bhat, I. A., & Arumugam, G. (2021, October). Construction, validation and standardization of general self-confidence scale. In *International conference on emotions and multidisciplinary approaches-ICEMA* (p. 121).
- Bhat, I. A., & Arumugam, G. (2020). Teacher effectiveness and job satisfaction of secondary school teachers of Kashmir valley. *Journal of Xi'an University of Architecture & Technology*, 7(2), 3038-3044.
- Ahmad Bhat, I., & Arumugam, G. (2021). Development and Validation of General Mathematical Anxiety Scale. *European Online Journal of Natural and Social Sciences*, 10(4), pp-619.
- Dar, S. A., & Lone, D. N. A. (2022). Make in India an analytic study of the country's technological shift for transformation. *International Journal of Information Technology & Amp*, 6-16.
- Dar, S. A., & Lone, D. N. A. (2022). Lockdowns in Jammu and Kashmir: The Human Rights Consequences. *Journal of Legal Subjects (JLS)* ISSN, 1-11.
- Dar, S. A. (2022). The Role and Awareness of E-Governance in Kashmir A Study of Kupwara District. *Journal of Psychology and Political Science (JPPS)* ISSN, 2799-1024.
- Dar, S. A., & Nagrath, D. (2022). Are Women a Soft Target for Cyber Crime in India. *Journal of Information Technology and Computing*, 3(1), 23-31.
- Dar, S. A., Lone, N. A., & Shairgojri, A. A. (2022). Plagiarism is Unethical: So Be Original and Don't Plagiarize. *Central Asian journal of arts and design*, 3(6), 21-29.
- Dar, S. A. (2022). RTI: A Powerful Tool for Promoting Transparency in Jammu and Kashmir. *Journal of Psychology and Political Science (JPPS)* ISSN, 2799-1024.

- Dar, S. A., & Nagrath, D. (2022). DIGITAL INDIA WHERE KNOWLEDGE IS STRENGTH-AND EMPOWERS THE PEOPLE. *American Journal of Interdisciplinary Research and Development*, 5, 259-269.
- Ahmad, P. A. (2022). Is the Coalition Government a Success Story in the Indian Politics?. *Traditional Journal of Law and Social Sciences*, 1(01), 83-92.
- Dar, S. A., & Shaigojri, A. A. (2022). ICT: An Innovative Move to Promote Gender Equality and Sustainable Future for Women in India. *LC International Journal of STEM (ISSN: 2708-7123)*, 3(2), 179-185.
- Ahmad, S. (2022). Direct Benefit Transfer: The Great Technological Move of India. *JOURNAL OF DIGITAL LEARNING AND DISTANCE EDUCATION*, 1(1), 37-41.
- Gerding, D. N., & Tedesco, F. J. (2019). *The problem of antibiotic resistance: Current status and future directions*. *Journal of Antimicrobial Chemotherapy*, 74(7), 1993-1997. <https://doi.org/10.1093/jac/dkz151>
- Ginsburg, A. S., & Pokorny, J. (2018). *Strategies for promoting antibiotic development in a time of resistance*. *Infectious Disease Clinics of North America*, 32(3), 535-551. <https://doi.org/10.1016/j.idc.2018.04.001>
- Gupta, A., & Sharma, R. (2019). *Emerging therapeutic strategies against multidrug-resistant bacterial infections*. *Therapeutic Advances in Infectious Disease*, 6(5), 169-182. <https://doi.org/10.1177/2049936119880136>
- Laxminarayan, R., & Malani, A. (2007). *Antibiotic resistance: A looming crisis*. *The Lancet Infectious Diseases*, 7(8), 443-451. [https://doi.org/10.1016/S1473-3099\(07\)70239-0](https://doi.org/10.1016/S1473-3099(07)70239-0)
- Rupp, M. E., & Fey, P. D. (2003). *Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, treatment, and infection control*. *Clinical Infectious Diseases*, 36(7), 1003-1010. <https://doi.org/10.1086/373117>
- Walsh, C. (2018). *Antibiotics: Actions, origins, resistance*. American Society for Microbiology Press.
- Wernli, D., & Zeltner, T. (2019). *Global health policy and the fight against antimicrobial resistance*. *Global Health Action*, 12(1), 1707418. <https://doi.org/10.1080/16549716.2019.1707418>
- Wright, G. D. (2010). *Resistance to antibiotics: Theoretic and practical implications*. *Current Opinion in Microbiology*, 13(5), 498-502. <https://doi.org/10.1016/j.mib.2010.06.006>
- Zhao, F., & Haugland, R. (2017). *Efforts to address antibiotic resistance in clinical settings*. *The Journal of Clinical Microbiology*, 55(7), 1813-1822. <https://doi.org/10.1128/JCM.00144-17>
- Zong, Z., & Liu, Y. (2017). *Current status and future directions in the development of antibiotic resistance mechanisms*. *Trends in Microbiology*, 25(12), 970-978. <https://doi.org/10.1016/j.tim.2017.06.001>
- Shaigojri, A. A., & Dar, S. A. (2021). Voices from India's Borderlands against the Citizenship Amendment Act (CAA-2019) An Explanatory study. *Journal of Psychology and Political Science (JPPS) ISSN, 2799-1024*.
- Shaigojri, A. A. (2022). Indian Nationalism: Redefined in Today's Time. *Journal of Psychology and Political Science (JPPS) ISSN, 2799-1024*.
- Shaigojri, A. A. (2022). Impact Analysis of Information and Communication Technology (ICT) on Diplomacy. *Journal of Learning and Educational Policy (JLEP) ISSN, 2799-1121*.
- Shaigojri, A. A. (2022). Russia vs. Ukraine War: India's stance. *Journal of Psychology and Political Science (JPPS) ISSN, 2799-1024*.
- Shaigojri, A. A. (2021). India's Soft Power as a Pillar of Foreign Policy. *Journal of Corporate Finance Management and Banking System (JCFMBS) ISSN, 2799-1059*.
- Shaigojri, A. A., & Bhat, R. M. (2023). MUSLIM WOMEN AND POLITICS OF INDIA. *MORFAI JOURNAL*, 2 (4), 760, 766.
- Lone, A. S., Shah Nawaz, M., Singh, N., Pervez, S., & Ravindran, K. C. (2023). Metabolomic and antioxidant potential analyses of the rhizome and leaves of *Podophyllum hexandrum* Royle: A comparative account. *Biocatalysis and Agricultural Biotechnology*, 52, 102836.

- Lone, A. S., Ravindran, K. C., & Jeandet, P. (2024). Evaluation of antimicrobial activity and bioactive compound analysis of *Verbascum thapsus* L. A folklore medicinal plant. *Phytomedicine Plus*, 4(3), 100560.
- Lone, A. S. (2023). PLANT POWER: HARNESSING THE HEALING POTENTIAL OF PHYTOCHEMISTRY. *Jurnal Mahasiswa Agribisnis*, 2(1), 25-31.
- Gerding, D. N., & Tedesco, F. J. (2019). *The problem of antibiotic resistance: Current status and future directions*. *Journal of Antimicrobial Chemotherapy*, 74(7), 1993-1997. <https://doi.org/10.1093/jac/dkz151>
- Ginsburg, A. S., & Pokorny, J. (2018). *Strategies for promoting antibiotic development in a time of resistance*. *Infectious Disease Clinics of North America*, 32(3), 535-551. <https://doi.org/10.1016/j.idc.2018.04.001>
- Gupta, A., & Sharma, R. (2019). *Emerging therapeutic strategies against multidrug-resistant bacterial infections*. *Therapeutic Advances in Infectious Disease*, 6(5), 169-182. <https://doi.org/10.1177/2049936119880136>
- Laxminarayan, R., & Malani, A. (2007). *Antibiotic resistance: A looming crisis*. *The Lancet Infectious Diseases*, 7(8), 443-451. [https://doi.org/10.1016/S1473-3099\(07\)70239-0](https://doi.org/10.1016/S1473-3099(07)70239-0)
- Rupp, M. E., & Fey, P. D. (2003). *Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, treatment, and infection control*. *Clinical Infectious Diseases*, 36(7), 1003-1010. <https://doi.org/10.1086/373117>
- Walsh, C. (2018). *Antibiotics: Actions, origins, resistance*. American Society for Microbiology Press.
- Wernli, D., & Zeltner, T. (2019). *Global health policy and the fight against antimicrobial resistance*. *Global Health Action*, 12(1), 1707418. <https://doi.org/10.1080/16549716.2019.1707418>
- Wright, G. D. (2010). *Resistance to antibiotics: Theoretic and practical implications*. *Current Opinion in Microbiology*, 13(5), 498-502. <https://doi.org/10.1016/j.mib.2010.06.006>
- Zhao, F., & Haugland, R. (2017). *Efforts to address antibiotic resistance in clinical settings*. *The Journal of Clinical Microbiology*, 55(7), 1813-1822. <https://doi.org/10.1128/JCM.00144-17>
- Zong, Z., & Liu, Y. (2017). *Current status and future directions in the development of antibiotic resistance mechanisms*. *Trends in Microbiology*, 25(12), 970-978. <https://doi.org/10.1016/j.tim.2017.06.001>
- Bhat, R. M. (2024). Feudalism in early medieval Kashmir. *Cogent Arts & Humanities*, 11(1), 2392393.
- Bhat, R. M. (2023). DR. BHIM RAO AMBEDKAR'S ADVOCACY OF WOMEN RIGHTS. *MORFAI JOURNAL*, 2(4), 730-736.
- Ahmad, P. A. (2021). Cyber Security Is More than Just a Question of Information Technology. *Journal of Image Processing and Intelligent Remote Sensing (JIPIRS) ISSN*, 2815-0953.
- Mir, B. A., & Somasundaran, K. (2019). Psychological impact among women due to armed conflict in district Shopian, Jammu and Kashmir. *Research Journal ARTS*, 18(1), 133-143.
- Ahmad, P. A. (2022). Is Getting Into Student Politics In India A Waste Of Time. *Journal of Women Empowerment and Studies (JWES) ISSN*, 2799-1253.
- Bhat, R. M., & Ahmad, P. A. (2022). Social Media and the Cyber Crimes Against Women-A Study. *Journal of Image Processing and Intelligent Remote Sensing (JIPIRS) ISSN*, 2815-0953.
- Bhat, R. M. (2023). ECONOMIC GOVERNANCE AND PUBLIC FINANCE IN KAUTILYA'S ARTHASHASTRA. *International Journal of Social Science, Educational, Economics, Agriculture Research and Technology*, 2(7), 211-218.
- Ahmad, P. A. (2022). Impact of armed conflict on tourism in Kashmir. *Morfai Journal*, 2(2), 403-408.
- Ahmad, P. A. (2022). Is Getting Into Student Politics In India A Waste Of Time. *Journal of Women Empowerment and Studies (JWES) ISSN*, 2799-1253.
- Mir, B. (2024). Impact of Abrogation of Article 370 on Tourism and Development: A Study of Kashmir Valley. *South India Journal of Social Sciences*, 22(2), 71-80.

- Gerding, D. N., & Tedesco, F. J. (2019). *The problem of antibiotic resistance: Current status and future directions*. *Journal of Antimicrobial Chemotherapy*, 74(7), 1993-1997. <https://doi.org/10.1093/jac/dkz151>
- Ginsburg, A. S., & Pokorny, J. (2018). *Strategies for promoting antibiotic development in a time of resistance*. *Infectious Disease Clinics of North America*, 32(3), 535-551. <https://doi.org/10.1016/j.idc.2018.04.001>
- Gupta, A., & Sharma, R. (2019). *Emerging therapeutic strategies against multidrug-resistant bacterial infections*. *Therapeutic Advances in Infectious Disease*, 6(5), 169-182. <https://doi.org/10.1177/2049936119880136>
- Laxminarayan, R., & Malani, A. (2007). *Antibiotic resistance: A looming crisis*. *The Lancet Infectious Diseases*, 7(8), 443-451. [https://doi.org/10.1016/S1473-3099\(07\)70239-0](https://doi.org/10.1016/S1473-3099(07)70239-0)
- Rupp, M. E., & Fey, P. D. (2003). *Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, treatment, and infection control*. *Clinical Infectious Diseases*, 36(7), 1003-1010. <https://doi.org/10.1086/373117>
- Walsh, C. (2018). *Antibiotics: Actions, origins, resistance*. American Society for Microbiology Press.
- Wernli, D., & Zeltner, T. (2019). *Global health policy and the fight against antimicrobial resistance*. *Global Health Action*, 12(1), 1707418. <https://doi.org/10.1080/16549716.2019.1707418>
- Wright, G. D. (2010). *Resistance to antibiotics: Theoretic and practical implications*. *Current Opinion in Microbiology*, 13(5), 498-502. <https://doi.org/10.1016/j.mib.2010.06.006>
- Zhao, F., & Haugland, R. (2017). *Efforts to address antibiotic resistance in clinical settings*. *The Journal of Clinical Microbiology*, 55(7), 1813-1822. <https://doi.org/10.1128/JCM.00144-17>
- Zong, Z., & Liu, Y. (2017). *Current status and future directions in the development of antibiotic resistance mechanisms*. *Trends in Microbiology*, 25(12), 970-978. <https://doi.org/10.1016/j.tim.2017.06.001>